Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $740,000 on 1 April 2026, according to an SEC filing. The transaction, executed under a Rule 10b5-1 trading plan adopted in June, represented 2.33% of his direct holdings and follows a roughly 300% share price increase over the past year. The sale appears to be routine profit-taking rather than a change in outlook. Spyre recently accelerated a key clinical catalyst, with its SKYWAY rheumatoid arthritis sub-study now expected to deliver topline data in Q3 2026 after completing enrolment ahead of schedule. Additional readouts across psoriatic arthritis and axial spondyloarthritis remain on track for Q4. The biotechnology company, valued at $4 billion, develops monoclonal antibody therapeutics targeting inflammatory bowel disease.

Apr. 7, 2016- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial public offering of 5,000,000 shares

Spyre Therapeutics has raised investor attention following a 127% one-year total return, despite a recent 2.5% one-day decline. The stock trades at $41.25, approximately 47% below the average analyst price target of $60.79. The company's price-to-book ratio of 5.8x sits well above the US biotechs industry average of 2.5x, though below a peer group average of 9.4x. This suggests the market is pricing in significant premium for its inflammatory bowel disease and rheumatic conditions pipeline. Spyre Therapeutics remains loss-making, reporting net losses of $126.5 million and generating less than $1 million in revenue. The elevated valuation relative to its balance sheet reflects investor expectations for future growth, though clinical programme outcomes remain uncertain.